These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 28679779)
1. Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer. Jing Y; Chavez V; Ban Y; Acquavella N; El-Ashry D; Pronin A; Chen X; Merchan JR Mol Cancer Res; 2017 Oct; 15(10):1410-1420. PubMed ID: 28679779 [TBL] [Abstract][Full Text] [Related]
2. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845 [TBL] [Abstract][Full Text] [Related]
3. In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer. Jing Y; Bejarano MT; Zaias J; Merchan JR Breast Cancer Res Treat; 2015 Jan; 149(1):99-108. PubMed ID: 25519042 [TBL] [Abstract][Full Text] [Related]
4. In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models. Jing Y; Zaias J; Duncan R; Russell SJ; Merchan JR Gene Ther; 2014 Mar; 21(3):289-97. PubMed ID: 24430235 [TBL] [Abstract][Full Text] [Related]
5. In vivo antitumor activity by dual stromal and tumor-targeted oncolytic measles viruses. Jing Y; Chavez V; Khatwani N; Ban Y; Espejo AP; Chen X; Merchan JR Cancer Gene Ther; 2020 Dec; 27(12):910-922. PubMed ID: 32231231 [TBL] [Abstract][Full Text] [Related]
6. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Hildenbrand R; Schaaf A Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473 [TBL] [Abstract][Full Text] [Related]
7. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment. Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740 [TBL] [Abstract][Full Text] [Related]
8. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact. Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533 [TBL] [Abstract][Full Text] [Related]
9. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy. Panagioti E; Kurokawa C; Viker K; Ammayappan A; Anderson SK; Sotiriou S; Chatzopoulos K; Ayasoufi K; Johnson AJ; Iankov ID; Galanis E J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34196308 [TBL] [Abstract][Full Text] [Related]
10. Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma. Li M; Li G; Kiyokawa J; Tirmizi Z; Richardson LG; Ning J; Das S; Martuza RL; Stemmer-Rachamimov A; Rabkin SD; Wakimoto H Acta Neuropathol Commun; 2020 Dec; 8(1):221. PubMed ID: 33308315 [TBL] [Abstract][Full Text] [Related]
11. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway. Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777 [TBL] [Abstract][Full Text] [Related]
12. Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors. Studebaker AW; Hutzen B; Pierson CR; Shaffer TA; Raffel C; Jackson EM Neuro Oncol; 2015 Dec; 17(12):1568-77. PubMed ID: 25838138 [TBL] [Abstract][Full Text] [Related]
13. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872 [TBL] [Abstract][Full Text] [Related]
14. Measles to the Rescue: A Review of Oncolytic Measles Virus. Aref S; Bailey K; Fielding A Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084 [TBL] [Abstract][Full Text] [Related]
15. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Iankov ID; Blechacz B; Liu C; Schmeckpeper JD; Tarara JE; Federspiel MJ; Caplice N; Russell SJ Mol Ther; 2007 Jan; 15(1):114-22. PubMed ID: 17164782 [TBL] [Abstract][Full Text] [Related]
16. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager. de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154 [TBL] [Abstract][Full Text] [Related]
17. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion. Magnussen SN; Hadler-Olsen E; Costea DE; Berg E; Jacobsen CC; Mortensen B; Salo T; Martinez-Zubiaurre I; Winberg JO; Uhlin-Hansen L; Svineng G BMC Cancer; 2017 May; 17(1):350. PubMed ID: 28526008 [TBL] [Abstract][Full Text] [Related]
18. Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR. Almholt K; Lærum OD; Nielsen BS; Lund IK; Lund LR; Rømer J; Jögi A Clin Exp Metastasis; 2015 Aug; 32(6):543-54. PubMed ID: 26040548 [TBL] [Abstract][Full Text] [Related]
19. Engineered measles virus as a novel oncolytic therapy against prostate cancer. Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133 [TBL] [Abstract][Full Text] [Related]